Alto Neuroscience Inc. has announced the completion of patient enrollment in its Phase 2 proof-of-concept clinical trial evaluating ALTO-101 for the treatment of cognitive impairment associated with schizophrenia $(CIAS)$. The study enrolled 83 patients across 13 clinical sites in the United States and utilizes a randomized, double-blind, placebo-controlled crossover design to assess the effects of ALTO-101, a novel transdermal phosphodiesterase-4 (PDE4) inhibitor, on electroencephalography (EEG) measures and cognitive endpoints. Baseline results from the trial have replicated findings from previous independent datasets, supporting the use of theta ITC as a biomarker for cognitive impairment in CIAS. Topline data from the study are expected to be reported following completion of dosing and data analysis, anticipated around the end of the first quarter.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alto Neuroscience Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260213343048) on February 13, 2026, and is solely responsible for the information contained therein.